tradingkey.logo
tradingkey.logo
Buscar

Terns Pharmaceuticals Inc

TERN
Añadir a la lista de seguimiento
52.950USD
0.0000.00%
Cierre 05/13, 16:00ETCotizaciones retrasadas 15 min
6.12BCap. mercado
PérdidaP/E TTM

Terns Pharmaceuticals Inc

52.950
0.0000.00%

Más Datos de Terns Pharmaceuticals Inc Compañía

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Información de Terns Pharmaceuticals Inc

Símbolo de cotizaciónTERN
Nombre de la empresaTerns Pharmaceuticals Inc
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoBurroughs (Amy L)
Número de empleados59
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
Dirección1065 East Hillsdale Blvd., Suite 100
CiudadFOSTER CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94404
Teléfono16505255535
Sitio Webhttps://ternspharma.com/
Símbolo de cotizaciónTERN
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoBurroughs (Amy L)

Ejecutivos de Terns Pharmaceuticals Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Director
Independent Director
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Morgan Stanley & Co. LLC
6.77%
BlackRock Institutional Trust Company, N.A.
5.73%
Adage Capital Management, L.P.
4.80%
Vivo Capital, LLC
4.45%
Vestal Point Capital, LP
3.90%
Otro
74.35%
Accionistas
Accionistas
Proporción
Morgan Stanley & Co. LLC
6.77%
BlackRock Institutional Trust Company, N.A.
5.73%
Adage Capital Management, L.P.
4.80%
Vivo Capital, LLC
4.45%
Vestal Point Capital, LP
3.90%
Otro
74.35%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
31.48%
Investment Advisor/Hedge Fund
30.63%
Hedge Fund
28.80%
Research Firm
9.56%
Venture Capital
5.23%
Private Equity
2.14%
Pension Fund
1.67%
Bank and Trust
0.35%
Sovereign Wealth Fund
0.34%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
478
133.90M
115.93%
+29.44M
2025Q4
376
92.69M
87.28%
-19.26M
2025Q3
346
91.95M
105.09%
-23.09M
2025Q2
344
88.08M
100.66%
-23.35M
2025Q1
352
90.67M
103.82%
-24.88M
2024Q4
339
91.95M
108.28%
-13.40M
2024Q3
310
84.11M
100.51%
-7.48M
2024Q2
277
70.14M
99.60%
-17.86M
2024Q1
253
68.60M
105.57%
-10.37M
2023Q4
237
68.12M
109.36%
-7.25M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Morgan Stanley & Co. LLC
7.83M
6.78%
+287.70K
+3.82%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
6.61M
5.73%
+1.58M
+31.36%
Dec 31, 2025
Adage Capital Management, L.P.
5.55M
4.81%
+1.61M
+40.90%
Dec 31, 2025
Vivo Capital, LLC
5.14M
4.46%
-204.91K
-3.83%
Jan 31, 2026
Vestal Point Capital, LP
4.50M
3.9%
+4.50M
--
Dec 31, 2025
Avoro Capital Advisors LLC
4.35M
3.77%
+4.35M
--
Dec 31, 2025
Janus Henderson Investors
3.38M
2.93%
+3.38M
--
Dec 31, 2025
Citadel Advisors LLC
3.17M
2.74%
+1.58M
+99.24%
Dec 31, 2025
Capitolis Liquid Global Markets LLC
3.05M
2.64%
+3.05M
--
Dec 31, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Roundhill GLP-1 & Weight Loss ETF
2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.44%
Virtus LifeSci Biotech Clinical Trials ETF
1.42%
State Street SPDR S&P Pharmaceuticals ETF
0.83%
Tema Oncology ETF
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.39%
ALPS Medical Breakthroughs ETF
0.3%
ProShares Ultra Nasdaq Biotechnology
0.3%
iShares Russell 2000 Value ETF
0.13%
iShares Micro-Cap ETF
0.11%
Ver más
Roundhill GLP-1 & Weight Loss ETF
Proporción2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.44%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.42%
State Street SPDR S&P Pharmaceuticals ETF
Proporción0.83%
Tema Oncology ETF
Proporción0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.39%
ALPS Medical Breakthroughs ETF
Proporción0.3%
ProShares Ultra Nasdaq Biotechnology
Proporción0.3%
iShares Russell 2000 Value ETF
Proporción0.13%
iShares Micro-Cap ETF
Proporción0.11%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI